The invention includes a toothpaste or other orally applied product to be used at least once daily to help prevent or inhibit the acquisition of a number of infections by oral or pharyngeal tissues, particularly including the “common” cold. These compositions possess a combination of ingredients that is not found in other toothpastes or other orally applied products, and these ingredients work together to synergistically interfere with the acquisition of a number of pathogens. The toothpastes will have the usual dentifrice ingredients known to prevent tooth decay, as well as those that reduce halitosis (i.e., bad breath), and prevent gingivitis. In addition, the toothpastes will include one or more of: 1) GALALCOOL® as an individual compound, and not as an extract component; 2) zinc protoporphyrin IX; and 3) one or more other colorless or low-color tannin(s) each as an individual compound, and not as an extract component.

The invention includes a toothpaste or other orally applied product to be used at least once daily to help prevent or inhibit the acquisition of a number of infections by oral or pharyngeal tissues, particularly including the “common” cold. These compositions possess a combination of ingredients that is not found in other toothpastes or other orally applied products, and these ingredients work together to synergistically interfere with the acquisition of a number of pathogens. The toothpastes will have the usual dentifrice ingredients known to prevent tooth decay, as well as those that reduce halitosis (i.e., bad breath), and prevent gingivitis. In addition, the toothpastes will include one or more of: 1) GALALCOOL® as an individual compound, and not as an extract component; 2) zinc protoporphyrin IX; and 3) one or more other colorless or low-color tannin(s) each as an individual compound, and not as an extract component.

The invention includes a toothpaste or other orally applied product to be used at least once daily to help prevent or inhibit the acquisition of a number of infections by oral or pharyngeal tissues, particularly including the “common” cold. These compositions possess a combination of ingredients that is not found in other toothpastes or other orally applied products, and these ingredients work together to synergistically interfere with the acquisition of a number of pathogens. The toothpastes will have the usual dentifrice ingredients known to prevent tooth decay, as well as those that reduce halitosis (i.e., bad breath), and prevent gingivitis. In addition, the toothpastes will include one or more of: 1) GALALCOOL® as an individual compound, and not as an extract component; 2) zinc protoporphyrin IX; and 3) one or more other colorless or low-color tannin(s) each as an individual compound, and not as an extract component.

The present invention relates to the use of pharmaceutically acceptable zinc salts, preferably water soluble zinc salts alone or optionally, in combination with one or more of a protein pump inhibitor (PPI), H2 blocker, anti-H. pylori antibiotic/antimicrobial, cytoprotective agent or a combination agent as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, raising the pH of the stomach during resting phase as well as decreasing the duration of stomach acid release during a secretagogue phase and for treating conditions including gastroesophageal reflux disease (GERD), non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZE disease), ulcer disease, and gastric cancer, as well as preventing or reducing the likelihood of ulcer disease. In addition, the present methods are useful for treating patients who are non-responsive to proton pump inhibitors (PPI) and as an alternative to traditional therapies or conditions which are caused by rapid and complete inhibition of secretagogue induced acid secretion.

The present invention relates to the use of pharmaceutically acceptable zinc salts, preferably water soluble zinc salts alone or optionally, in combination with one or more of a protein pump inhibitor (PPI), H2 blocker, anti-H. pylori antibiotic/antimicrobial, cytoprotective agent or a combination agent as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, raising the pH of the stomach during resting phase as well as decreasing the duration of stomach acid release during a secretagogue phase and for treating conditions including gastroesophageal reflux disease (GERD), non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZE disease), ulcer disease, and gastric cancer, as well as preventing or reducing the likelihood of ulcer disease. In addition, the present methods are useful for treating patients who are non-responsive to proton pump inhibitors (PPI) and as an alternative to traditional therapies or conditions which are caused by rapid and complete inhibition of secretagogue induced acid secretion.

The present invention relates to the use of pharmaceutically acceptable zinc salts, preferably water soluble zinc salts alone or optionally, in combination with one or more of a protein pump inhibitor (PPI), H2 blocker, anti-H. pylori antibiotic/antimicrobial, cytoprotective agent or a combination agent as otherwise described herein for providing fast action with optional long duration effect in reducing gastric acid secretion, raising the pH of the stomach during resting phase as well as decreasing the duration of stomach acid release during a secretagogue phase and for treating conditions including gastroesophageal reflux disease (GERD), non-erosive reflux disease (NERD), Zollinger-Ellison syndrome (ZE disease), ulcer disease, and gastric cancer, as well as preventing or reducing the likelihood of ulcer disease. In addition, the present methods are useful for treating patients who are non-responsive to proton pump inhibitors (PPI) and as an alternative to traditional therapies or conditions which are caused by rapid and complete inhibition of secretagogue induced acid secretion.

Combined multistage microbial preparations for enhancement of the biological skin barrier and maintenance of healthy skin microbiota are disclosed. The preparations are useful in chronic problems associated with dysbiosis such as atopic dermatitis, acne, rosacea and vitiligo or acute problems caused by damage of the skin such as burns, cuts and contusions.

Combined multistage microbial preparations for enhancement of the biological skin barrier and maintenance of healthy skin microbiota are disclosed. The preparations are useful in chronic problems associated with dysbiosis such as atopic dermatitis, acne, rosacea and vitiligo or acute problems caused by damage of the skin such as burns, cuts and contusions.

The present invention relates to compositions for human consumption of tailored dietary supplements or nutraceuticals, comprised of various components including, among others, vitamins and minerals, provided in various permutations, in multiple daily doses, based on an individual's age and gender, bioavailability, and synergistic and competing properties of the components, thereby promoting general wellbeing and healthiness.

The present invention relates to compositions for human consumption of tailored dietary supplements or nutraceuticals, comprised of various components including, among others, vitamins and minerals, provided in various permutations, in multiple daily doses, based on an individual's age and gender, bioavailability, and synergistic and competing properties of the components, thereby promoting general wellbeing and healthiness.